Núria Gavaldà Batalla

Title: Innovations by Núria Gavaldà Batalla

Introduction

Núria Gavaldà Batalla is a prominent inventor based in Barcelona, Spain. He has made significant contributions to the field of biotechnology, particularly in the treatment of transthyretin-associated amyloidosis. With a total of 4 patents to his name, his work is paving the way for new therapeutic approaches.

Latest Patents

One of his latest patents focuses on a therapy for transthyretin-associated amyloidosis. This patent provides a catechol-O-methyltransferase (COMT) inhibitor for use in the prevention and/or treatment of this condition. Additionally, it outlines the use of the COMT inhibitor in combination therapy with other agents, including another COMT inhibitor, a benzoxazole derivative, iododiflunisal, diflunisal, resveratrol, tauroursodeoxycholic acid, doxocycline, or epigallocatechin-3-gallate. This innovative approach highlights his commitment to advancing medical treatments.

Career Highlights

Núria Gavaldà Batalla is currently associated with Som Innovation Biotech, S.L., where he continues to develop groundbreaking therapies. His work is characterized by a strong focus on improving patient outcomes through innovative solutions.

Collaborations

He collaborates with notable colleagues, including Marc Centellas Casado and Raúl Insa Boronat. These partnerships enhance the research and development efforts at Som Innovation Biotech, S.L.

Conclusion

Núria Gavaldà Batalla's contributions to biotechnology and his innovative patents are making a significant impact in the field of medicine. His dedication to developing effective therapies for transthyretin-associated amyloidosis showcases the importance of innovation in healthcare.